Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy

COVID-19 Risk Assessment Hospitalization Outcomes Epidemiology Efficacy

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions

Who May Be Eligible (Plain English)

Who May Qualify: - COVID-19 PCR positive - COVID-19 PCR negative - COVID-19 PCR pending - COVID-19 high risk score Who Should NOT Join This Trial: - Subjects unwilling to participate in the study before, during or after consent - Patients considered unreliable by the investigator concerning the requirements for follow-up visits. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * COVID-19 PCR positive * COVID-19 PCR negative * COVID-19 PCR pending * COVID-19 high risk score Exclusion Criteria: * Subjects unwilling to participate in the study before, during or after consent * Patients considered unreliable by the investigator concerning the requirements for follow-up visits.

Treatments Being Tested

DRUG

Coromec Registry with ECL-19

Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology

Locations (3)

Multiple Locations
Phoenix, Arizona, United States
Multiple Locations
Bangalore, India
Multiple Locations
Stockholm, Sweden